Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H14N2 |
| Molecular Weight | 198.2637 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC=CC=N1)C2=CC=CC=C2
InChI
InChIKey=FWUQWDCOOWEXRY-ZDUSSCGKSA-N
InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1
| Molecular Formula | C13H14N2 |
| Molecular Weight | 198.2637 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25259653/ |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LANICEMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25259653/ |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LANICEMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
16.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25259653/ |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LANICEMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. | 2001 Dec |
|
| Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study. | 2001 Feb |
|
| On the relationship between plasma concentrations of drugs and outcome of stroke studies in laboratory animals. | 2001 Jun |
|
| Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. | 2001 Jun |
|
| Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice. | 2002 Mar 15 |
|
| Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study. | 2002 May |
|
| Effect of low-affinity NMDA receptor antagonists on electrical activity in mouse cortical slices. | 2002 May 17 |
|
| Assessment of cognitive and motor deficits in a marmoset model of stroke. | 2003 |
|
| Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. | 2003 May 16 |
|
| NXY-059: a hopeful sign in the treatment of stroke. | 2006 Oct |
|
| Glutamate receptor-mediated inhibition of L-glutamate efflux from cerebral cortex in vitro. | 2006 Oct 9 |
Patents
Sample Use Guides
50-150 mg of the drug is given as a single intravenous (iv) infusion over 60 minutes.
Route of Administration:
Intravenous
Rat cortical neurons were exposed to NMDA (50 uM) or glutamate (50 uM) for 15 min, the treatment resulted in the death of 85-95% of the neurons during the next 24 h. Lanicemine inhibited the neurotoxicity at 50 uM, prevented the loss of membrane-associated protein kinase C activity and reduced by approximately 35% the magnitude of NMDA-triggered increases in intracellular free Ca2+ concentration in the cortical cultures.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:02:37 GMT 2023
by
admin
on
Sat Dec 16 17:02:37 GMT 2023
|
| Record UNII |
9TMU325RK3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1509
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9TMU325RK3
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
7943
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
9794203
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
Lanicemine
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
DTXSID30870011
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107647
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
C77601
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
100000174979
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
153322-05-5
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY | |||
|
DB11889
Created by
admin on Sat Dec 16 17:02:37 GMT 2023 , Edited by admin on Sat Dec 16 17:02:37 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
